You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on cancer immunotherapy.
The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
The project is collaborating with nine biopharma companies to combine more real-world clinical data with genomic data.
The researchers identified specific macrophage and conventional dendritic cell subsets as key mediators of cellular crosstalk in the tumor microenvironment.
A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.
Two recent acquisitions have resulted in the swift launch of two assays, one for the clinic and another for research use, as the firm's original test finally nears validation.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.
The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.
In PNAS this week: immune gene expression differences in blood of young adults, molecular contributors to cells' microtubule and actin networks, and more.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.
CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.
A study of Great Danes homes in on a genomic region linked to fearfulness.
In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.